Covid-19 roundup: FDA authorizes Pfizer/BioNTech vaccine for 12- to 15-year-olds; Novavax shares sink as company delays vaccine timeline
Back-to-school season could look much different this year, as Pfizer and BioNTech’s Covid-19 vaccine has become the first in the US to be authorized for children as young as 12 years old.
On Monday, the FDA expanded its emergency use authorization for the jab — which was originally OK’d for those 16 years and older — based on efficacy data from 190 adolescents which showed their immune response to the vaccine was at least as good as the response seen in older participants.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.